Steven Naids, MD
Ophthalmology · Boynton Beach, FLNPI 1487917530
Payments from drug & device makers
Across 373 payments — averaging $140.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$14K
- Eyevance Pharmaceuticals LLC$14K
- AbbVie$13K
- Mallinckrodt Enterprises LLC$4K
- Novartis$1K
- Alcon$498
- plus $6K from 29 others
What the payments were for
- Consulting fees$10,40020%
- Speaking & faculty fees$29,30056%
- Travel & lodging$1,5773%
- Food & beverage$10,85221%
- Education$1400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 39 | $14,270 |
| Eyevance Pharmaceuticals LLC | 30 | $13,680 |
| AbbVie(2 entities) | 92 | $13,030 |
| Mallinckrodt Enterprises LLC | 9 | $4,032 |
| Novartis | 35 | $1,194 |
| Alcon | 15 | $498 |
| Thea Pharma Inc. | 2 | $491 |
| Johnson & Johnson Surgical Vision, Inc. | 11 | $471 |
| NEW World Medical,inc. | 11 | $453 |
| Kala Pharmaceuticals, Inc. | 7 | $449 |
| Tarsus Pharmaceuticals, Inc. | 10 | $416 |
| Bausch & Lomb Americas Inc. | 13 | $357 |
| Glaukos Corporation | 5 | $357 |
| Shire North American Group Inc | 9 | $353 |
| Dompe US, Inc. | 8 | $266 |
| Aerie Pharmaceuticals, Inc. | 8 | $246 |
| Akorn, Inc. | 12 | $235 |
| Harrow Eye, LLC | 8 | $211 |
| Sun Pharmaceutical Industries Inc. | 9 | $185 |
| Amgen(2 entities) | 4 | $163 |
| Rayner Intraocular Lenses Limited | 2 | $144 |
| Optos, Inc. | 1 | $117 |
| Ocular Therapeutix, Inc. | 6 | $105 |
| Akorn Operating Company LLC | 5 | $97 |
| ANI Pharmaceuticals, Inc. | 3 | $72 |
| Mallinckrodt Hospital Products Inc. | 3 | $65 |
| Astellas Pharma US Inc | 2 | $63 |
| Oyster Point Pharma, Inc. | 3 | $57 |
| Sight Sciences, Inc. | 3 | $54 |
| Carl Zeiss Meditec USA, Inc. | 2 | $40 |
| Lensar, Inc. | 2 | $27 |
| Rxsight Inc | 1 | $25 |
| Eyepoint US, Inc. | 1 | $21 |
| Biotissue Holdings Inc. | 1 | $15 |
| Quidel Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOTEMAX SM$13,490
- VUITY$10,523
- Tobradex ST$6,759
- Zerviate$4,589
- Flarex$4,400
- ACTHAR$3,815
- RESTASIS$675
- XIIDRA$466
- IYUZEH$400
- INVELTYS$350
- XDEMVY$264
- EYSUVIS$226
- iDoseTR$156
- Tecnis IOL$147
- DURYSTA$129
- PROLENSA$125
- MIEBO$125
- RayOne EMV$123
- RayOne Spheric$123
- RayOne Aspheric$123
How this compares
$52,269 in reported general payments places this provider in the 85th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 595 | $461,600 |
| XiidraLifitegrast | 127 | $110,760 |
| LumiganBimatoprost | 219 | $90,868 |
| XdemvyLotilaner | 16 | $30,148 |
| CombiganBrimonidine Tartrate/Timolol | 78 | $29,280 |
| Cyclosporine | 59 | $27,277 |
| EysuvisLoteprednol Etabonate | 35 | $17,013 |
| VyzultaLatanoprostene Bunod | 46 | $15,582 |
| Prednisolone Acetate | 383 | $14,198 |
| Latanoprost | 1,566 | $13,919 |
| Lotemax SmLoteprednol Etabonate | 48 | $11,899 |
| RocklatanNetarsudil Mesylat/Latanoprost | 13 | $10,874 |
| Alphagan PBrimonidine Tartrate | 21 | $9,835 |
| Restasis MultidoseCyclosporine | 16 | $9,827 |
| IlevroNepafenac | 24 | $8,892 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P, Restasis Multidose | $13,030 | $601,411929 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $357 | $126,342173 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $416 | $30,14816 claims |
| NovartisIlevro, Travatan Z | $1,194 | $17,56041 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $449 | $17,01335 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $246 | $15,84925 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate | $14,270 | $13,62362 claims |
| AlconSimbrinza | $498 | $6,45331 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Boynton Beach
- Sirtaz SibiaBoynton Beach$445K
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
- Matthew CunninghamOrlando$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.